Why is Dr Reddy's Labs falling/rising?

As of 14-Jul, Dr Reddys Laboratories Ltd is currently priced at 1,250.95, reflecting a decrease of 2.8, or 0.22%. The stock has been underperforming, having fallen consecutively for the last five days, resulting in a total decline of 4.38% over that period. Additionally, the stock's performance today has underperformed its sector by 1.12%. While the stock is trading higher than its 100-day and 200-day moving averages, it is below its 5-day, 20-day, and 50-day moving averages. The delivery volume has also decreased significantly, falling by 38.86% against the 5-day average, indicating a decline in investor participation. Despite the company's strong long-term fundamentals, including low debt and healthy growth in net sales and operating profit, the recent flat results and consistent underperformance against benchmarks have negatively impacted investor sentiment.
In the broader market context, Dr Reddys Laboratories has shown a short-term return of -4.38% over the past week, which contrasts sharply with the Sensex's decline of only 1.42% during the same period. This underperformance is part of a larger trend, as the stock has generated a return of -6.95% over the past year, consistently lagging behind the BSE500 in each of the last three annual periods. The high institutional holdings at 62.91% suggest that these investors have the resources to analyze the company's fundamentals, yet the stock's recent struggles and flat quarterly results have raised concerns, contributing to its current downward trajectory.